- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00098241
Safety & Efficacy of Certican in Pediatric de Novo Renal Transplant Patients
February 21, 2017 updated by: Novartis Pharmaceuticals
Multicenter Trial of the Safety & Efficacy of Certican in Pediatric de Novo Renal Transplant Patients
The purpose of this study is to evaluate the safety and tolerability of RAD001 (Certican) administered to pediatric renal transplant recipients, and to provide additional safety data.
Study Overview
Study Type
Interventional
Enrollment (Anticipated)
45
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Leuven, Belgium, 3000
- Dienst Pediatrie UZ Gasthuisberg, Herestraat 49
-
-
-
-
Ohio
-
Columbus, Ohio, United States, 43205-2696
- Columbus Children's Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
1 year to 14 years (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male and female patients no more than 16 years of age.
- Patients receiving a primary cadaveric or non-HLA identical living donor (related or unrelated) renal transplant.
- The graft must be functional within 48 hours post transplantation.
Exclusion Criteria:
- Cold ischemia time greater than 40 hours.
- Patients who are recipients of multiple solid organ transplants, including dual and en bloc kidneys, or who have previously received transplanted organs.
- Patients with panel reactive T cell antibodies of 50 % or higher at the last assessment before transplantation.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Safety and tolerability at 6 and 12 Months as measured by adverse events, laboratory abnormalities and infections.
|
Secondary Outcome Measures
Outcome Measure |
---|
Efficacy at 6 and 12 Months as measured by rejection, graft loss, death and loss to follow up.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2000
Primary Completion (Actual)
March 1, 2007
Study Completion (Actual)
March 1, 2007
Study Registration Dates
First Submitted
December 3, 2004
First Submitted That Met QC Criteria
December 3, 2004
First Posted (Estimate)
December 6, 2004
Study Record Updates
Last Update Posted (Actual)
February 23, 2017
Last Update Submitted That Met QC Criteria
February 21, 2017
Last Verified
February 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CRAD001AB351
- RAD/Certican
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Kidney Transplantation
-
Astellas Pharma IncAstellas Pharma Europe B.V.CompletedKidney Transplantation | Renal Transplantation | Transplantation, Kidney | Grafting, Kidney | Transplantation, RenalBelgium, Germany, Spain, Sweden, Italy, Switzerland, United Kingdom, Austria, France, Poland, Czech Republic, Netherlands
-
Bristol-Myers SquibbCompletedKidney Transplantation: Transplantation, Kidney
-
Nantes University HospitalTerminated
-
Hospices Civils de LyonCompletedKidney Transplantation | Pancreas-kidney TransplantationFrance
-
Astellas Pharma Europe Ltd.CompletedLiver Transplantation | Kidney Transplantation | Heart TransplantationCzechia, France, Italy, Poland, United Kingdom
-
The Hospital for Sick ChildrenCompletedLiver Transplantation | Kidney Transplantation | Heart TransplantationCanada
-
Astellas Pharma Europe Ltd.TerminatedLiver Transplantation | Kidney Transplantation | Heart TransplantationBelgium, France, Germany, Poland, Spain, United Kingdom
-
Astellas Pharma Europe Ltd.CompletedLiver Transplantation | Kidney Transplantation | Heart TransplantationSpain, Australia, France, Germany, Canada, Italy, United Kingdom, Belgium, South Africa, Switzerland, Sweden, United States, Austria, Brazil, Czechia, Denmark, Finland, Hungary, Ireland, Mexico, Netherlands, New Zealand, Poland
-
Astellas Pharma Europe Ltd.CompletedLiver Transplantation | Kidney Transplantation | Heart TransplantationBelgium, France, Germany, Poland, Spain, United Kingdom
-
Medical University of ViennaUnknownKidney Function After Transplantation | Outcome After Kidney Transplantation
Clinical Trials on Certican
-
Hospital Universitário São JoséUnknownDisorder Related to Renal TransplantationBrazil
-
Novartis PharmaceuticalsWithdrawnKidney TransplantationSwitzerland
-
Azienda Ospedaliera di PadovaUnknownLiver Diseases | Liver Failure | Liver Cirrhosis | Liver NeoplasmsItaly
-
Ahmad TarhiniNovartis PharmaceuticalsCompletedSmall Cell Lung CancerUnited States
-
University of CologneCompletedGraft-versus-Host DiseaseGermany
-
Novartis PharmaceuticalsCompletedAutosomal Dominant Polycystic Kidney DiseaseGermany, Austria, France
-
Novartis PharmaceuticalsCompleted
-
National Health Research Institutes, TaiwanNovartisUnknownHepatocellular CarcinomaTaiwan
-
Children's Hospital Medical Center, CincinnatiNovartisCompletedEpilepsy | Tuberous Sclerosis ComplexUnited States
-
University of UtahNovartisTerminatedPeutz-Jeghers SyndromeUnited States